Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could umbilical cord stem cells help failing kidneys?

NCT ID NCT07240987

Disease control Sponsor: The First Affiliated Hospital of Air Force Medicial University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether a single intravenous infusion of stem cells from donated umbilical cord tissue can safely improve kidney function in 32 adults with stage 3 or 4 chronic kidney disease caused by diabetes or high blood pressure. Participants will be randomly assigned to receive either the stem cells or a placebo (salt water) and will be followed for one year. The main goal is to see if the treatment can raise the kidney's filtration rate and reduce protein in the urine, which are signs of better kidney health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
umbilical cord mesenchymal stem cells (MSCs)
What this could lead to
If it works, this could point toward a new way to slow or partly reverse kidney decline in chronic kidney disease, potentially delaying the need for dialysis or transplant.
What could go wrong
This is a very early (Phase 1/2) and small (32 people) trial, so results may not be conclusive. Stem cell infusions carry risks like allergic reactions or infection, and the treatment may not improve kidney function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Agreement to participate in the trial and provision of signed written informed consent * Pathological diagnosis of diabetic nephropathy or hypertensive renal damage * 15 ≤ eGFR \< 60 mL/min/1.73m², UACR \> 300 mg/g * Age ≥ 18 years Exclusion Criteria: * Extremely severe anemia (hemoglobin \< 30 g/L) * Received blood product transfusion therapy within 1 month * Autosomal dominant or recessive polycystic kidney disease (ADPKD) * History of kidney transplant or other solid organ transplant * Active systemic or localized infection (e.g., pneumonia, osteomyelitis) * Allergy to stem cells themselves or stem cell-related culture medium * History of allergic reaction to cell products (e.g., blood transfusion, platelets) * History of coagulation disorders (thromboembolism, pulmonary embolism, deep vein thrombosis) * History of malignancy or current malignant disease * Elevated tumor markers (AFP, CEA, CA199, CA125, etc.) * Pregnant women or women with plans for pregnancy within 3 months after MSC therapy * Participation in drug-related clinical trials within the past 2 months * Any form of drug abuse, mental illness, or other conditions considered by the investigator as potentially affecting the trial's validity or the subject's health

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic kidney disease (DKD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome diabetic kidney disease hypertensive nephropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic kidney disease (DKD) Hypertensive nephropathy Kidney disease, chronic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.